This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT01280344 |
|---|---|
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Helsinn Therapeutics (U.S.), Inc |
| Enrollment | 320 participants |
| Design | Interventional, Randomized, Parallel, Masking: Quadruple |
| Conditions | Gastrointestinal Dysmotility |
| Interventions | Saline Solution for Injection; Ipamorelin |
| Start | Apr 2011 |
| Primary completion | Jun 2013 |
| Study completion | May 2014 |
| Results posted | Not yet |
| Registry last updated | Apr 13, 2017 |
Compounds on this site that cite this trial
What the registry says the trial is about
Post-operative administration of ipamorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial small and/or large bowel resection.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Recovery of Gastrointestinal (GI) Function | Up to 10 days |
2 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
